Dublin, May 08, 2018 (GLOBE NEWSWIRE) -- The "Global Oncology Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.
Market Analysis:The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018-2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.
The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.
Applications Analysis: The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.
The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011-2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers.
Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines.
The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.
Key Topics Covered:
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 Total Addressable Market
1.4 Trends Of Cancer Therapy Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition - Infoholic Research
3.2 Segmented Addressable Market (Sam)
3.3 Trends Of The Oncology Drugs Market
3.4 Related Markets
3.4.1 Over The Counter Drugs (Otc)
3.4.2 Active Pharmaceutical Ingredients (Apis)
3.4.3 Diabetes Drugs
4 Market Outlook
4.1 Oncology Drugs Approved By Fda (2014 - 2018)
4.2 Market Segmentation
4.3 Pest Analysis
4.4 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO - Global Oncology Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing Incidence Of Cancer Across The Globe
5.1.1.2 Growing Geriatric Population
5.1.1.3 Expiration Of Patents
5.1.2 Opportunities
5.1.2.1 Growing Focus On Personalized Medicine
5.1.2.2 Increasing Healthcare Spending
5.1.3 Restraints
5.1.3.1 High Cost Of The Drug
5.1.3.2 Side Effects Of Oncology Drugs
6 Therapeutic Modality: Market Size And Analysis
6.1 Overview
6.2 Chemotherapy
6.3 Targeted Therapy
6.4 Immunotherapy
6.5 Others
7 Application: Market Size And Analysis
7.1 Overview
7.2 Blood Cancer
7.3 Breast Cancer
7.4 Gastro Intestinal Cancer
7.5 Lung Cancer
7.6 Prostate Cancer
7.7 Others
8 Regions: Market Size And Analysis
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.3.4 France
8.3.5 Italy
8.4 Apac
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest Of The World
9 Competitive Landscape
9.1 Overview
10 Vendor Profiles
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Bristol-Myers Squibb
- Celgene Corporation
- Johnson & Johnson
- Pfizer Inc.
11 Companies To Watch For
- Astra Zenca Plc
- Eli Lilly And Company.
- Glaxosmithkline Plc
- Merck & Co.
- Sanofi
- Amgen Inc.
- Abbvie, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/dmgnnw/global_oncology?w=12